Outsourcing

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Articles

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

How Fast Is Too Fast?

Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Catalent to Manufacture J&J’s Lead COVID-19 Vaccine Candidate

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Delivering the Goods

Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.


Keeping Toxicity to a Minimum

Can investing in early formulation studies drive a new therapy successfully across the commercialization finish line?

Fast vs. Formulated?

Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.

ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement

Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech. 

Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost. 

Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization

Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.

Catalent to Acquire MaSTherCell Global for $315 Million

Shreekant Karmarkar, PhD, is president, DAT Pharma Consulting, Inc., skarmarkar@DATPharmaConsulting.com, 1-224-383-4493

How to adopt win-win strategies and understand quality agreements for complying with cGMP when building strategic relationships with pharmaceutical contract research organizations.

Building Strategic Relationships with CROs

CMOs and CDMOs expanded their services and facilities in 2019 and early 2020.

Contract Development Services